(Total Views: 3237)
Posted On: 03/15/2025 12:00:17 PM
Post# of 154867
Sean: Perhaps because Michelle Kilcoyne left CYDY in 2023 as her bio, posted here yesterday, stated. Perhaps a better question would be why is CYDY's website showing job openings for Ms Kilcoyne's former position of Director of Clinical Trials as well as for a Project Manager, given that its CRC clinical trial was expected to launch this quarter.
A plausible answer to the above question would jibe Respert's analysis that CYDY management would much prefer to avoid the time and expense of building out a go it alone in-house drug development structure in favor of having a BP partnership/eventual BO doing that heavy lifting. In that vein, the fact that these 2 jobs remain open is consistent with the premise that an oncology partnership is on the near horizon.
A plausible answer to the above question would jibe Respert's analysis that CYDY management would much prefer to avoid the time and expense of building out a go it alone in-house drug development structure in favor of having a BP partnership/eventual BO doing that heavy lifting. In that vein, the fact that these 2 jobs remain open is consistent with the premise that an oncology partnership is on the near horizon.
(18)
(0)
